Market capitalization | $152.48m |
Enterprise Value | $108.82m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 3.61 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-25.37m |
Free Cash Flow (TTM) Free Cash Flow | $-19.73m |
Cash position | $61.31m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
6 Analysts have issued a Achieve Life Sciences, Inc. forecast:
6 Analysts have issued a Achieve Life Sciences, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.27 -0.27 |
4%
4%
|
|
EBITDA | -25 -25 |
36%
36%
|
EBIT (Operating Income) EBIT | -25 -25 |
36%
36%
|
Net Profit | -28 -28 |
34%
34%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
Head office | United States |
CEO | Richard Stewart |
Employees | 22 |
Founded | 1991 |
Website | www.achievelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.